Collaboration Exchange | President Zhu Meiling and Delegation from Shenzhen Traditional Chinese Medicine Hospital Visit Shenzhen Cell Valley

On the afternoon of March 7, 2024, a delegation from Shenzhen Traditional Chinese Medicine Hospital, including President Zhu Meiling, Vice President Chen Sheng, Director of Oncology Yang Zhenjiang, Director of Respiratory Medicine Xie Wei, Director of Gastroenterology Guo Shaoju, and Director of the GCP Office Liu Yu, visited Shenzhen Cell Valley. Our Chairman, Shi Yuanyuan; Chief Scientist, Wang Jianxun; and Deputy General Manager, Tang Xiaomeng, extended a warm welcome to the delegation.

First, accompanied by Professor Shi Yuanyuan, the Shenzhen TCM Hospital leaders toured the smart exhibition hall, production workshops, and R&D laboratories, gaining an initial understanding of the development background, corporate strength, product pipelines, and strategic layout of Shenzhen Cell Valley and its subsidiaries.

During the symposium, Professor Shi Yuanyuan extended a warm welcome to President Zhu Meiling, Vice President Chen Sheng, and their delegation. Head of Marketing, Sun Rui, provided a detailed overview of Shenzhen Cell Valley's core technologies, innovative achievements, and successful clinical cases in cell and gene therapy. Professor Shi noted that Shenzhen Cell Valley, as a one-stop service provider for cell and gene therapy solutions, offers clients full-process, professional, and efficient end-to-end industry chain services—from early-stage R&D, vector design, and viral production to cell manufacturing and regulatory application support. The company fully leverages the advantages of retroviral vectors in the industrialization of cell therapy drugs, providing innovative approaches for advancing basic research and clinical treatment, and delivering transformative solutions for the treatment of cancer and rare diseases.

President Zhu Meiling expressed high recognition of Shenzhen Cell Valley's achievements in research and clinical applications. She noted that cell therapy, as an emerging modern biomedical technology, is driving a paradigm shift in treatment represented by precision medicine, offering new strategies for the treatment of various diseases including cancer. She suggested that combining Traditional Chinese Medicine with cell therapy could exert synergistic effects, enhancing therapeutic outcomes and reducing adverse reactions, thereby further promoting its broad clinical application.

The two parties engaged in in-depth discussions on the integration of Traditional Chinese Medicine and modern medicine, joint project applications, and the establishment of a TCM-cell therapy platform, laying a solid foundation for future collaborative clinical research. They committed to working together to provide patients with more high-quality, precise, and efficient medical services.

About Shenzhen Traditional Chinese Medicine Hospital

Founded in 1975, Shenzhen Traditional Chinese Medicine Hospital comprises four campuses: Guangming, Futian, Acupuncture Hospital, and the Science and Education Center, along with affiliated institutions including the Shenzhen Institute of Traditional Chinese Medicine, the Shenzhen National TCM Window Talent Training Center, and the Shenzhen Traditional Chinese Medicine Preparation Center. The hospital became one of the first batch of grade-A tertiary TCM hospitals in China in 1995 and was selected as a key construction hospital in Guangdong Province's High-Level Hospital Program in 2021. The hospital currently employs over 2,500 staff, including more than 2,300 healthcare professionals, over 600 senior professionals, and nearly 60 national, provincial, and municipal distinguished TCM practitioners. The total value of medical equipment exceeds RMB 800 million.

Shenzhen TCM Hospital has established a tiered system of national, provincial, and municipal key specialties. It has been approved as a key TCM hospital under the National TCM Inheritance and Innovation Project, a National Regional TCM Diagnosis and Treatment Center (Liver Diseases), and a Guangdong-Hong Kong-Macao Greater Bay Area TCM Clinical Inheritance and Innovation Research Center. The hospital hosts a National Administration of Traditional Chinese Medicine (NATCM) Level III TCM Research Laboratory—the Clinical Cellular and Molecular Biology Laboratory, a National Drug Clinical Trial Institution (with 8 approved specialties), a National Medical Device Clinical Trial Institution (with 36 registered specialties), a Chinese Society of Traditional Chinese Medicine Clinical Pharmacist Training Base, a Shenzhen Key People's Livelihood Laboratory—the Modern Application Research Laboratory for Acupuncture, a Shenzhen Key Laboratory for TCM Preparation Research, and three Shenzhen Medical Innovation Platform Projects. The hospital is currently conducting over 160 research projects, has led major national science and technology projects under the "Eleventh Five-Year," "Twelfth Five-Year," and "Thirteenth Five-Year" plans, and has undertaken over 40 National Natural Science Foundation research projects, receiving more than 30 national, provincial, and municipal science and technology achievement awards. The hospital has 29 doctoral supervisors, 122 master's supervisors, and 36 clinical teaching departments, forming a multi-level educational system spanning doctoral, master's, and undergraduate programs.